201 related articles for article (PubMed ID: 33620103)
1. Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.
Ameri P; Tini G; Spallarossa P; Mercurio V; Tocchetti CG; Porto I
Br J Clin Pharmacol; 2021 Oct; 87(10):3690-3698. PubMed ID: 33620103
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib in idiopathic pulmonary fibrosis.
Woodcock HV; Maher TM
Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
7. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin V
Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
9. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib-induced glomerular microangiopathy: a case report.
Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Schmid U; Doege C; Dallinger C; Freiwald M
Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials.
Noth I; Wijsenbeek M; Kolb M; Bonella F; Moros L; Wachtlin D; Corte TJ
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285303
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
18. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Podolanczuk AJ; Cottin V
Adv Ther; 2023 May; 40(5):2038-2050. PubMed ID: 36928494
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
20. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data.
Lasky JA; Criner GJ; Lazarus HM; Kohlbrenner V; Bender S; Richeldi L
Adv Ther; 2020 Oct; 37(10):4209-4219. PubMed ID: 32767182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]